Helen J Gogas

39PUBLICATIONS
185CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Epidemiological modellingCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Oct 24, 2026
Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial.

|Aug 04, 2026
Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial.

|Jan 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Reinhard Dummer, Shibing Deng, Tao Xie

|Oct 18, 2025
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.

Georgina V Long, Charlie Garnett-Benson, Sonia Dolfi

|Jul 03, 2025
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047.

Evan J Lipson, Sonia Dolfi, Hao Tang

|Mar 27, 2025
Exploring the Dynamics of Immune Checkpoint Inhibitor-Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis.

Panagiotis T Diamantopoulos, Aikaterini Gkoufa, Amalia Anastasopoulou

Pageof 7

Frequent Collaborators

17 joint publications

Paolo Antonio Ascierto

11 joint publications

Georgina V Long

11 joint publications

Dirk Schadendorf

9 joint publications

Dimitrios C Ziogas